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Various studies have investigated whether single nucleotide polymorphisms (SNPs) in the 
gene purinergic receptor P2X7 (P2RX7), and rs2230912 specifically, were associated with 
mood disorders. While some studies found positive evidence, a large number of studies 
reported no significant associations. In a previously published meta-analysis, Feng et al. did 
not find a significant association and only moderate odds ratios (ORs) in case-control studies. 
They reported significant findings only for family-based studies. We revisited this finding and 
conducted a meta-analysis including 8,652 cases and 11,153 controls, adding unpublished 
results from the Munich Antidepressant Response Signature (MARS) study. We found a 
significant association between rs2230912 and combined mood disorders (major depressive 
disorder (MDD) or bipolar disorder (BD)) for the allelic, dominant and heterozygous-
2disadvantage model, all withstanding the threshold of correction for multiple testing. 
Stratifying by disorder revealed significant findings for the MDD-subgroup (OR of 1.12 for 
the allelic model), while the BD-subgroup presented with a lower effect size (OR of 1.05) and 
no significance. P2RX7 encodes a purinergic receptor which is expressed in the brain and also 
localized in immune cells.
Animal studies and functional studies will be necessary to enlighten its involvement in the 
etiology of mood disorders and its applicability for pharmacological purposes.
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Introduction
MDD and BD belong to the most common psychiatric diseases with a life-time prevalence of 
16% for MDD (Blazer et al. 1994) and 1-3.3% for BD (Jacobi et al. 2004). It is estimated that 
about 40% of the risk for developing MDD is due to genetic factors (Sullivan et al. 2000), for 
BD the estimates range from 80 to 90% (Kelsoe 2003). 
Linkage studies on BD (Curtis et al. 2003; Dawson et al. 1995; Ewald et al. 1998; Morissette 
et al. 1999; Shink et al. 2005) have identified a region of interest on 12q24 which was also 
reported to be involved in linkage for unipolar depression (Abkevich et al. 2003; McGuffin et 
al. 2005).
P2X, ligand-gated ion channel 7 (P2RX7), maps to this region and variations in the P2RX7 
gene have been investigated regarding their role in conferring susceptibility for affective 
disorders. Since the first report of an association with BD in a French Canadian family-based 
sample by Barden et al. (Barden et al. 2006) ten subsequent studies have been published 
testing associations of SNPs in P2RX7 and BD and/or MDD. Most studies considered 
exclusively the non-synonymous SNP rs2230912:A>G, which has been identified as the 
highest associated SNP in the first two published studies (Barden et al. 2006; Lucae et al. 
32006).  Rs2230912 is located in exon 13 and leads to a change of the amino acid glutamine to 
arginine at position 460 (Gln460Arg). While three studies reported association of this SNP 
(Lucae et al. 2006; McQuillin et al. 2009; Soronen et al. 2011), other studies did not detect 
significant associations with regard to case-control status (Backlund et al. 2012; Green et al. 
2009; Grigoroiu-Serbanescu et al. 2009; Halmai et al. 2013; Hejjas et al. 2009; Lavebratt et al. 
2010; Viikki et al. 2011; Yosifova et al. 2009).
P2RX7 encodes a purinergic receptor which is involved in Ca2+ dependent signal pathways. 
It is expressed in the brain and may regulate immune function and neurotransmitter release 
(Deuchars et al. 2001; Sperlagh et al. 2006). The activation of the receptor provides an 
inflammatory stimulus and regulates the release of pro-inflammatory cytokines. It could 
therefore regulate the link between nervous system and immune system (Skaper et al. 2010). 
Bennett (Bennett 2007) proposed that SNPs in P2RX7 modify the release of cytokines which 
could change the functional state of neural networks, and may lead to higher vulnerability for 
mood disorders. 
Feng and colleagues (Feng et al. 2014) published a meta-analysis and did not find significant 
association of rs2230912 with mood disorders in case-control samples. As we wanted to 
revise these findings and to further enlighten the controversial association reports concerning 
P2RX7, and rs2230912 in special, we conducted a meta-analysis taking into account the 
published case-control studies and adding results from an in-house sample (MARS study) 
which have not been published before. 
We included all published studies investigating association of rs2230912 with MDD as well 
as BD because there is a strong phenotypic overlap between both groups of patients. While 
both MDD and BD patients suffer from depressive episodes, bipolar patients in addition 
experience manic episodes. Furthermore, a constant lifetime diagnostic conversion rate of 
1.25 % per year from MDD to BD has been reported (Angst et al. 2005). However, the 
4genetic relationship of both disorders remains to be elucidated. Our results may help to further 
evaluate the potential role of P2RX7 in mood disorders.
Material and Methods
MARS Study
Unipolar depressive inpatients (demographic information in Table1) were recruited for the 
Munich Antidepressant Response Signature (MARS) project at the Max Planck Institute of 
Psychiatry in Munich, Germany (Hennings et al. 2009). Briefly, patients were included in the 
study within 1–3 days of admission to the hospital and diagnosis was ascertained according to 
the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV criteria. Patients 
fulfilling the criteria for at least a moderate depressive episode (HAM-D ≥ 14 on the 21-item 
Hamilton Depression Rating Scale) entered the analysis. Patients suffered from a first 
depressive episode or from a recurrent depressive disorder. All included patients were of 
European descent.
Control subjects were matched to the patient sample for age, gender and ethnicity from a 
randomly selected Munich-based community sample and underwent a strict screening-
procedure for the absence of psychiatric and severe somatic disease (Heck et al. 2009). The 
overall inclusion rate of all contacted probands was 50.3 %. These subjects thus represent a 
group of individuals from the general population who has never been mentally ill.
This study has been approved by the ethics committee of the Ludwig-Maximilians-University 
in Munich and written informed consent was obtained from all subjects.
Genotyping of the MARS study and quality control
On enrolment in the study, EDTA blood was drawn from each patient and control subject and 
DNA was extracted with the Puregene whole blood DNA-extraction kit (Gentra Systems Inc; 
MN) from fresh blood using standard DNA extraction procedures. SNP genotyping for 
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(Illumina Inc., San Diego, USA) according to the manufacturer’s standard protocols. The 
average call rate achieved was higher than 99%, with samples below 98% being either retyped 
or excluded from the study.  SNPs with a callrate below 98%, a deviation from Hardy-
Weinberg-Equilibrium (HWE) with a p-value < 1x10-05 or with a minor allele frequency 
below 5% were excluded. For statistical analysis presented in this paper, genotypes for 
rs2230912 were extracted. These were in HWE for cases (p=0.41) as well as in controls 
(p=0.40).
Search Strategy
We searched the PubMed database using the keywords “P2X7”, “P2RX7”, “depression”, 
“bipolar disorder” and “mood disorders”. All studies investigating the case-control association 
between rs2230912 and depression which were included in the database up to Jan 1st 2017 
were taken into the analysis. We also considered references from identified articles. In 
addition, we included an in-house sample (MARS study) for which results had not been 
published before. 
An overview of included studies is given in Table 2. The respective flow diagram is depicted 
in Figure 1.
Statistical Analysis
Genotypic distributions for BD/MDD cases and controls were derived from the respective 
publications. If these were not given in the paper, we contacted the authors and asked for 
more detailed information. This was successful for all but one study (Yosifova et al. 2009). 
Odds ratios, standard errors and p-values were calculated on the respective 2x2 tables using R 
(http://www.r-project.org/).  P-values were derived from the Wald-test using the R function 
6oddsratio. We tested three genetic models: allelic, dominant and hethom (i.e. heterozygous 
disadvantage model).
Meta-analyses for all three models were applied using the Metasoft-Package 
(http://genetics.cs.ucla.edu/meta/). As there was evidence for heterogeneity of effects between 
the studies (heterogeneity p-value= 0.015 allelic model, p=0.021 dominant model, p=0.044 
hethom model), we applied a random effects meta-analysis using the method of Han and 
Eskin (Han and Eskin 2011).
Bonferroni’s method was applied to correct for the three tested models resulting in a p-value 
threshold of 0.017 (=0.05/3).
Funnel plots and tests for asymmetry were conducted using the R-library metafor 
(http://cran.r-project.org/web/packages/metafor/index.html), forest plots were created with the 
R-library rmeta (http://cran.r-project.org/web/packages/rmeta/index.html).
Power analysis was conducted based on 1,000 simulations. For these, we applied the formulas 
given in Han and Eskin (Han and Eskin 2011). In each run, we simulated genotype 
distributions for each study using the study-specific odds ratio, allele-frequency and case and 
control sample sizes. Afterwards, we calculated effect-size estimates and standard errors for 
each simulated dataset and ran a meta-analysis over all simulated sets. The power was 
calculated as the fraction of simulated meta-analysis p-values that was lower than the p-value 
threshold of 0.017. 
Results
We excluded the study of Nagy et al. (Nagy et al. 2008) as this was not based on a case-
control comparison.  Additionally we removed the study of Yosifova et al. (Yosifova et al. 
2009) as no effect size estimates were available here. Effect size estimates for the remaining 
studies as well as meta-analysis results are given in Table 3. The meta-analysis revealed 
associations for the allelic model, dominant and hethom model, all withstanding the threshold 
7of correction for multiple testing (p=0.011 allelic model, p=0.008 dominant model, p=0.009 
hethom model). Forest plots and funnel plots for all three models are depicted in Figure 2.
Inspection of funnel plots and Egger’s test for asymmetry yielded no evidence for publication 
bias (p=0.206 allelic model, p=0.161 dominant model, p=0.286 hethom model).
In the meta-analysis, we had a power of 89% to detect associations between rs2230912 and 
mood-disorders withstanding correction for multiple testing.
Stratifying by disorder was possible for all studies except for Lavebratt et al. and Hejjas et al. 
where no disease-specific individual genotype distributions nor effect size estimates were 
given. In the meta-analysis of 4,182 MDD cases versus 5,926 controls (including the studies 
of Lucae et al., Green et al., Grigoroiu-Serbanescu et al. –German sample, Soronen et al., 
Vikii et al., Halmai et al. and the MARS study), all models were nominal significant (p=0.002 
allelic, p=0.037 dominant, p=0.028 hethom model), however only the allelic model withstood 
correction for multiple testing.
For BD only, the total sample size was 3,813 cases versus 6,691 controls (Barden et al., Green 
et al., McQuillin et al., Grigoroiu-Serbanescu et al. , Soronen et al., Halmai et al., Backlund et 
al.). This resulted in no significant p-values in the meta-analysis (p=0.136, allelic, p=0.135, 
dominant, p=0.271 hethom model).  Effect sizes for MDD were higher (OR of 1.12 for the 
allelic model in the meta-analysis) as compared to BP (OR of 1.05 for the same model). As 
most of the studies looked at a combined MDD/BP case sample in comparison to controls, 
separation of controls was not possible. Hence, most of the controls overlap between the 
stratified MDD and BD meta-analysis.
Discussion
In this meta-analysis we revisit the controversial association findings which have been 
reported for rs2230912 and mood disorders. 
8Although Feng et al. (Feng et al. 2014) reported lack of association in their meta-analysis in 
case-control samples, we found that rs2230912 was significantly associated with MDD/BD. 
Our study was well-powered, our result withstood correction for multiple testing and we did 
not find any evidence for publication bias. 
This contradictory result could be explained by the fact that the set of studies included in our 
analysis differs from the studies included by Feng and colleagues. They excluded the results 
from Lucae et al. (Lucae et al. 2006) due to deviation from Hardy-Weinberg-Equilibrium 
(HWE). Different reasons could be responsible for this deviation. First, this could be due to 
genotyping error. However, as Lucae et al. mention in their publication, they re-genotyped 
rs2230912 using a different genotyping technique and could confirm the genotypic 
distribution. Second, if heterozygotes represented with the high-risk genotype and if controls 
were screened for mental disorders, a lack of heterozygotes in the control group can be 
expected. In that case, the control group would not be in the HWE. This is also in line with 
the study of Aprile-Garcia et al. (Aprile-Garcia et al. 2016) who showed that the heterozygous 
state of the SNP impairs receptor function with respect to calcium influx, channel currents and 
intracellular signaling and hence this state is probably the risk state. Furthermore, rs2230912 
is just slightly out of HWE (p=0.03), and this p-value would not withstand correction for 
multiple testing over all included studies, we therefore decided to leave the results from Lucae 
et al. in our analysis. To clarify if our meta-analysis was mainly driven by the study of Lucae 
et al., we also ran an analysis after exclusion of the Lucae study. The allelic model was still 
nominally significant (p=0.031) while other models were not (p=0.089 dominant model, 
p=0.191 hethom model). The result for the allelic model did not survive multiple testing 
correction. However, one should take into account that this study was also one of the largest 
one with over 2,000 individuals. The fact that we detected only nominal significance could 
hence also be due to the reduced sample size. 
9No individual genotype counts nor effect size estimates were available for the study by 
Yosifova and colleagues (Yosifova et al. 2009) to us, therefore we had to exclude these 
findings from our analysis.
In comparison to Feng et al. we added a new study (Halmai et al. 2013) to the analysis as well 
as a new dataset for which results on rs2230912 have not been published before. Feng et al. 
excluded the study of Backlund et al. due to “duplicate report”. However we checked with the 
authors of the studies published by Backlund et al. and Lavebratt et al. and they ensured that 
samples for the case-control analyses did not overlap. Therefore we kept both studies in the 
meta-analysis.
A possible critique of our study might be that we included studies on major depression as well 
as on bipolar disorder. We were interested whether rs2230912 was associated with mood 
disorders in general. Furthermore, there is a strong phenotypic overlap between both groups 
of patients. For those studies, where stratifying into MDD and BP was possible, we 
additionally ran separate meta-analyses.  For the MDD sub-cohort the allelic model withstood 
correction for multiple testing, while no model was significantly associated for the BD sub-
cohort. While we found comparable effect sizes for the combined MDD/BP sample as Feng et 
al., our findings with regard to stratification differ. While Feng et. al report an OR of 1.01 for 
MDD only and of 1.08 for BP only, we observed larger effect sizes for the MDD-cohorts 
(OR=1.14 for the allelic model) as compared to the BP cohort (OR=1.05 for the allelic 
model).  
We focused on one single SNP in our meta-analysis. A broader approach involving more 
SNPs and ideally tagging all variation of the P2RX7 locus will be necessary to determine to 
what extent P2RX7 itself is involved in mood disorders. 
Another important point needs to be addressed. While some cohorts (Lucae et al., Hejjas et 
al., McQuillin et al., Grigoroiu et al. – Romanian subsample, Lavebratt et al.,  Soronen et al., 
Viiki et al., Halmai et al., MARS study) used screened controls, all other studies included in 
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our meta-analysis included unscreened controls. With the prevalence of 16% for MDD and of 
1% for BP in the general population, we cannot exclude that some of these controls were in 
fact suffering from mood disorders. If we restricted our meta-analysis to the cohorts with 
screened controls only, in general our effect size estimates increased and the meta-analysis p-
values decreased. Future studies should therefore focus on screened controls, otherwise results 
might be biased.
Furthermore, we included studies which explicitly investigated if P2RX7, and rs2230912 
specifically, was associated with mood disorders. Large genome-wide scale consortial studies 
of course also implicitly checked for association with this SNP. However, using the public 
available data from the Psychiatric Genomics Consortium (Major Depressive Disorder 
Working Group of the Psychiatric et al. 2013; Psychiatric 2011) whose MDD cohort also 
contains the sample of Lucae et al and the MARS study, rs2230912 was not significantly 
associated with neither MDD nor BP. The PGC is one of the largest studies to date that 
examined genome-wide associations with MDD or BP. Together with the great benefit of the 
very large sample-size, the cohorts are also very heterogenous and mostly used unscreened 
population controls and often non-clinical cases. Effects of rs2230912 might only present in 
more homogenous samples with regard to disease status, disease severity and screening. 
Taking all our findings together and considering that a minor change in included studies led to 
different results in the meta-analysis, it seems evident that more studies are necessary to 
determine if rs2230912 is associated with mood disorders. Ideally these studies should be 
recruited as homogenously as possible. In future, the inclusion of larger studies may also 
allow to look more closely into whether our findings with regard to higher effect-sizes for 
MDD as compared to BP can be replicated and also to stratify by sex or different ethnicities. 
Furthermore, more focused studies on the SNP-effect in animal models could help to 
enlighten which genetic model exactly describes the association in the best way.
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MDD and BD belong to the most common psychiatric diseases with a life-time prevalence of 
16% for MDD (Blazer et al. 1994) and 1-3.3% for BD (Jacobi et al. 2004). It is estimated that 
about 40% of the risk for developing MDD is due to genetic factors (Sullivan et al. 2000), for 
BD the estimates range from 80 to 90% (Kelsoe 2003). 
Linkage studies on BD (Curtis et al. 2003; Dawson et al. 1995; Ewald et al. 1998; Morissette 
et al. 1999; Shink et al. 2005) have identified a region of interest on 12q24 which was also 
reported to be involved in linkage for unipolar depression (Abkevich et al. 2003; McGuffin et 
al. 2005).
P2X, ligand-gated ion channel 7 (P2RX7), maps to this region and variations in the P2RX7 
gene have been investigated regarding their role in conferring susceptibility for affective 
disorders. Since the first report of an association with BD in a French Canadian family-based 
sample by Barden et al. (Barden et al. 2006) ten subsequent studies have been published 
testing associations of SNPs in P2RX7 and BD and/or MDD. Most studies considered 
exclusively the non-synonymous SNP rs2230912:A>G, which has been identified as the 
highest associated SNP in the first two published studies (Barden et al. 2006; Lucae et al. 
32006).  Rs2230912 is located in exon 13 and leads to a change of the amino acid glutamine to 
arginine at position 460 (Gln460Arg). While three studies reported association of this SNP 
(Lucae et al. 2006; McQuillin et al. 2009; Soronen et al. 2011), other studies did not detect 
significant associations with regard to case-control status (Backlund et al. 2012; Green et al. 
2009; Grigoroiu-Serbanescu et al. 2009; Halmai et al. 2013; Hejjas et al. 2009; Lavebratt et al. 
2010; Viikki et al. 2011; Yosifova et al. 2009).
P2RX7 encodes a purinergic receptor which is involved in Ca2+ dependent signal pathways. 
It is expressed in the brain and may regulate immune function and neurotransmitter release 
(Deuchars et al. 2001; Sperlagh et al. 2006). The activation of the receptor provides an 
inflammatory stimulus and regulates the release of pro-inflammatory cytokines. It could 
therefore regulate the link between nervous system and immune system (Skaper et al. 2010). 
Bennett (Bennett 2007) proposed that SNPs in P2RX7 modify the release of cytokines which 
could change the functional state of neural networks, and may lead to higher vulnerability for 
mood disorders. 
Feng and colleagues (Feng et al. 2014) published a meta-analysis and did not find significant 
association of rs2230912 with mood disorders in case-control samples. As we wanted to 
revise these findings and to further enlighten the controversial association reports concerning 
P2RX7, and rs2230912 in special, we conducted a meta-analysis taking into account the 
published case-control studies and adding results from an in-house sample (MARS study) 
which have not been published before. 
We included all published studies investigating association of rs2230912 with MDD as well 
as BD because there is a strong phenotypic overlap between both groups of patients. While 
both MDD and BD patients suffer from depressive episodes, bipolar patients in addition 
experience manic episodes. Furthermore, a constant lifetime diagnostic conversion rate of 
1.25 % per year from MDD to BD has been reported (Angst et al. 2005). However, the 
4genetic relationship of both disorders remains to be elucidated. Our results may help to further 
evaluate the potential role of P2RX7 in mood disorders.
Material and Methods
MARS Study
Unipolar depressive inpatients (demographic information in Table1) were recruited for the 
Munich Antidepressant Response Signature (MARS) project at the Max Planck Institute of 
Psychiatry in Munich, Germany (Hennings et al. 2009). Briefly, patients were included in the 
study within 1–3 days of admission to the hospital and diagnosis was ascertained according to 
the Diagnostic and Statistical Manual of Mental Disorders (DSM) IV criteria. Patients 
fulfilling the criteria for at least a moderate depressive episode (HAM-D ≥ 14 on the 21-item 
Hamilton Depression Rating Scale) entered the analysis. Patients suffered from a first 
depressive episode or from a recurrent depressive disorder. All included patients were of 
European descent.
Control subjects were matched to the patient sample for age, gender and ethnicity from a 
randomly selected Munich-based community sample and underwent a strict screening-
procedure for the absence of psychiatric and severe somatic disease (Heck et al. 2009). The 
overall inclusion rate of all contacted probands was 50.3 %. These subjects thus represent a 
group of individuals from the general population who has never been mentally ill.
This study has been approved by the ethics committee of the Ludwig-Maximilians-University 
in Munich and written informed consent was obtained from all subjects.
Genotyping of the MARS study and quality control
On enrolment in the study, EDTA blood was drawn from each patient and control subject and 
DNA was extracted with the Puregene whole blood DNA-extraction kit (Gentra Systems Inc; 
MN) from fresh blood using standard DNA extraction procedures. SNP genotyping for 
5patients and controls was performed on Illumina 317k and 610k Genotyping BeadChips 
(Illumina Inc., San Diego, USA) according to the manufacturer’s standard protocols. The 
average call rate achieved was higher than 99%, with samples below 98% being either retyped 
or excluded from the study.  SNPs with a callrate below 98%, a deviation from Hardy-
Weinberg-Equilibrium (HWE) with a p-value < 1x10-05 or with a minor allele frequency 
below 5% were excluded. For statistical analysis presented in this paper, genotypes for 
rs2230912 were extracted. These were in HWE for cases (p=0.41) as well as in controls 
(p=0.40).
Search Strategy
We searched the PubMed database using the keywords “P2X7”, “P2RX7”, “depression”, 
“bipolar disorder” and “mood disorders”. All studies investigating the case-control association 
between rs2230912 and depression which were included in the database up to Jan 1st 2017 
were taken into the analysis. We also considered references from identified articles. In 
addition, we included an in-house sample (MARS study) for which results had not been 
published before. 
An overview of included studies is given in Table 2. The respective flow diagram is depicted 
in Figure 1.
Statistical Analysis
Genotypic distributions for BD/MDD cases and controls were derived from the respective 
publications. If these were not given in the paper, we contacted the authors and asked for 
more detailed information. This was successful for all but one study (Yosifova et al. 2009). 
Odds ratios, standard errors and p-values were calculated on the respective 2x2 tables using R 
(http://www.r-project.org/).  P-values were derived from the Wald-test using the R function 
6oddsratio. We tested three genetic models: allelic, dominant and hethom (i.e. heterozygous 
disadvantage model).
Meta-analyses for all three models were applied using the Metasoft-Package 
(http://genetics.cs.ucla.edu/meta/). As there was evidence for heterogeneity of effects between 
the studies (heterogeneity p-value= 0.015 allelic model, p=0.021 dominant model, p=0.044 
hethom model), we applied a random effects meta-analysis using the method of Han and 
Eskin (Han and Eskin 2011).
Bonferroni’s method was applied to correct for the three tested models resulting in a p-value 
threshold of 0.017 (=0.05/3).
Funnel plots and tests for asymmetry were conducted using the R-library metafor 
(http://cran.r-project.org/web/packages/metafor/index.html), forest plots were created with the 
R-library rmeta (http://cran.r-project.org/web/packages/rmeta/index.html).
Power analysis was conducted based on 1,000 simulations. For these, we applied the formulas 
given in Han and Eskin (Han and Eskin 2011). In each run, we simulated genotype 
distributions for each study using the study-specific odds ratio, allele-frequency and case and 
control sample sizes. Afterwards, we calculated effect-size estimates and standard errors for 
each simulated dataset and ran a meta-analysis over all simulated sets. The power was 
calculated as the fraction of simulated meta-analysis p-values that was lower than the p-value 
threshold of 0.017. 
Results
We excluded the study of Nagy et al. (Nagy et al. 2008) as this was not based on a case-
control comparison.  Additionally we removed the study of Yosifova et al. (Yosifova et al. 
2009) as no effect size estimates were available here. Effect size estimates for the remaining 
studies as well as meta-analysis results are given in Table 3. The meta-analysis revealed 
associations for the allelic model, dominant and hethom model, all withstanding the threshold 
7of correction for multiple testing (p=0.011 allelic model, p=0.008 dominant model, p=0.009 
hethom model). Forest plots and funnel plots for all three models are depicted in Figure 2.
Inspection of funnel plots and Egger’s test for asymmetry yielded no evidence for publication 
bias (p=0.206 allelic model, p=0.161 dominant model, p=0.286 hethom model).
In the meta-analysis, we had a power of 89% to detect associations between rs2230912 and 
mood-disorders withstanding correction for multiple testing.
Stratifying by disorder was possible for all studies except for Lavebratt et al. and Hejjas et al. 
where no disease-specific individual genotype distributions nor effect size estimates were 
given. In the meta-analysis of 4,182 MDD cases versus 5,926 controls (including the studies 
of Lucae et al., Green et al., Grigoroiu-Serbanescu et al. –German sample, Soronen et al., 
Vikii et al., Halmai et al. and the MARS study), all models were nominal significant (p=0.002 
allelic, p=0.037 dominant, p=0.028 hethom model), however only the allelic model withstood 
correction for multiple testing.
For BD only, the total sample size was 3,813 cases versus 6,691 controls (Barden et al., Green 
et al., McQuillin et al., Grigoroiu-Serbanescu et al. , Soronen et al., Halmai et al., Backlund et 
al.). This resulted in no significant p-values in the meta-analysis (p=0.136, allelic, p=0.135, 
dominant, p=0.271 hethom model).  Effect sizes for MDD were higher (OR of 1.12 for the 
allelic model in the meta-analysis) as compared to BP (OR of 1.05 for the same model). As 
most of the studies looked at a combined MDD/BP case sample in comparison to controls, 
separation of controls was not possible. Hence, most of the controls overlap between the 
stratified MDD and BD meta-analysis.
Discussion
In this meta-analysis we revisit the controversial association findings which have been 
reported for rs2230912 and mood disorders. 
8Although Feng et al. (Feng et al. 2014) reported lack of association in their meta-analysis in 
case-control samples, we found that rs2230912 was significantly associated with MDD/BD. 
Our study was well-powered, our result withstood correction for multiple testing and we did 
not find any evidence for publication bias. 
This contradictory result could be explained by the fact that the set of studies included in our 
analysis differs from the studies included by Feng and colleagues. They excluded the results 
from Lucae et al. (Lucae et al. 2006) due to deviation from Hardy-Weinberg-Equilibrium 
(HWE). Different reasons could be responsible for this deviation. First, this could be due to 
genotyping error. However, as Lucae et al. mention in their publication, they re-genotyped 
rs2230912 using a different genotyping technique and could confirm the genotypic 
distribution. Second, if heterozygotes represented with the high-risk genotype and if controls 
were screened for mental disorders, a lack of heterozygotes in the control group can be 
expected. In that case, the control group would not be in the HWE. This is also in line with 
the study of Aprile-Garcia et al. (Aprile-Garcia et al. 2016) who showed that the heterozygous 
state of the SNP impairs receptor function with respect to calcium influx, channel currents and 
intracellular signaling and hence this state is probably the risk state. Furthermore, rs2230912 
is just slightly out of HWE (p=0.03), and this p-value would not withstand correction for 
multiple testing over all included studies, we therefore decided to leave the results from Lucae 
et al. in our analysis. To clarify if our meta-analysis was mainly driven by the study of Lucae 
et al., we also ran an analysis after exclusion of the Lucae study. The allelic model was still 
nominally significant (p=0.031) while other models were not (p=0.089 dominant model, 
p=0.191 hethom model). The result for the allelic model did not survive multiple testing 
correction. However, one should take into account that this study was also one of the largest 
one with over 2,000 individuals. The fact that we detected only nominal significance could 
hence also be due to the reduced sample size. 
9No individual genotype counts nor effect size estimates were available for the study by 
Yosifova and colleagues (Yosifova et al. 2009) to us, therefore we had to exclude these 
findings from our analysis.
In comparison to Feng et al. we added a new study (Halmai et al. 2013) to the analysis as well 
as a new dataset for which results on rs2230912 have not been published before. Feng et al. 
excluded the study of Backlund et al. due to “duplicate report”. However we checked with the 
authors of the studies published by Backlund et al. and Lavebratt et al. and they ensured that 
samples for the case-control analyses did not overlap. Therefore we kept both studies in the 
meta-analysis.
A possible critique of our study might be that we included studies on major depression as well 
as on bipolar disorder. We were interested whether rs2230912 was associated with mood 
disorders in general. Furthermore, there is a strong phenotypic overlap between both groups 
of patients. For those studies, where stratifying into MDD and BP was possible, we 
additionally ran separate meta-analyses.  For the MDD sub-cohort the allelic model withstood 
correction for multiple testing, while no model was significantly associated for the BD sub-
cohort. While we found comparable effect sizes for the combined MDD/BP sample as Feng et 
al., our findings with regard to stratification differ. While Feng et. al report an OR of 1.01 for 
MDD only and of 1.08 for BP only, we observed larger effect sizes for the MDD-cohorts 
(OR=1.14 for the allelic model) as compared to the BP cohort (OR=1.05 for the allelic 
model).  
We focused on one single SNP in our meta-analysis. A broader approach involving more 
SNPs and ideally tagging all variation of the P2RX7 locus will be necessary to determine to 
what extent P2RX7 itself is involved in mood disorders. 
Another important point needs to be addressed. While some cohorts (Lucae et al., Hejjas et 
al., McQuillin et al., Grigoroiu et al. – Romanian subsample, Lavebratt et al.,  Soronen et al., 
Viiki et al., Halmai et al., MARS study) used screened controls, all other studies included in 
10
our meta-analysis included unscreened controls. With the prevalence of 16% for MDD and of 
1% for BP in the general population, we cannot exclude that some of these controls were in 
fact suffering from mood disorders. If we restricted our meta-analysis to the cohorts with 
screened controls only, in general our effect size estimates increased and the meta-analysis p-
values decreased. Future studies should therefore focus on screened controls, otherwise results 
might be biased.
Furthermore, we included studies which explicitly investigated if P2RX7, and rs2230912 
specifically, was associated with mood disorders. Large genome-wide scale consortial studies 
of course also implicitly checked for association with this SNP. However, using the public 
available data from the Psychiatric Genomics Consortium (Major Depressive Disorder 
Working Group of the Psychiatric et al. 2013; Psychiatric 2011) whose MDD cohort also 
contains the sample of Lucae et al and the MARS study, rs2230912 was not significantly 
associated with neither MDD nor BP. The PGC is one of the largest studies to date that 
examined genome-wide associations with MDD or BP. Together with the great benefit of the 
very large sample-size, the cohorts are also very heterogenous and mostly used unscreened 
population controls and often non-clinical cases. Effects of rs2230912 might only present in 
more homogenous samples with regard to disease status, disease severity and screening. 
Taking all our findings together and considering that a minor change in included studies led to 
different results in the meta-analysis, it seems evident that more studies are necessary to 
determine if rs2230912 is associated with mood disorders. Ideally these studies should be 
recruited as homogenously as possible. In future, the inclusion of larger studies may also 
allow to look more closely into whether our findings with regard to higher effect-sizes for 
MDD as compared to BP can be replicated and also to stratify by sex or different ethnicities. 
Furthermore, more focused studies on the SNP-effect in animal models could help to 
enlighten which genetic model exactly describes the association in the best way.
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Table 1: demographics of MARS study
unipolar cases controls p-value
n 832 540
n male 401 (48.2%) 244 (45.2 %) 0.31 a
age mean (sd) 48.31 (14.09) 47.39 (13.50) 0.23 b
a Based on Χ2-Square test for independence 
b Based on t-test for difference of means
Table 2: studies included in the meta-analysis
publication # cases type cases # controls reported 
association with 
rs2230912
Barden et al., 2006 213 BD 214 yes
Lucae et al., 2006 1,000 MDD 1,029 yes
Green et al., 2009 1,723 BD/MDD 1,204 no
Hejjas et al., 2009 171 BD/MDD 178 no
McQuillin et al., 2009 613 BD 560 yes
Grigoroiu-Serbanescu 
et al., 2009
2,091 BD/MDD 2,008 no
Yosifova et al., 2009a 172 BD 556 no
Lavebratt et al., 2010 457 BD/MDD 2,286 no
Soronen et al, 2011 450 BD/MDD 1,322 yes
Vikii et al, 2011 218 MDD 395 no
Halmai et al., 2013 315 BD/MDD 373 no
Backlund et al., 2012 b 569 BD 1,044 not given
MARS study 832 MDD 540 not published
a No individual genotypes were available for this study therefore it was not included in further 
analyses
b This publication studied rapid cycling and not BD per se. However, genotypic distributions for  
cases and controls were given, therefore we included the study in further analyses.







beta se p-value beta se p-value beta se p-value
Barden et al. 0.232 0.178 0.194 0.355 0.207 0.086 0.423 0.214 0.048
Lucae et al. 0.161 0.086 0.061 0.262 0.098 0.007 0.338 0.102 0.001
Green et al. 0.006 0.071 0.936 0.004 0.081 0.966 -0.001 0.083 0.995
Hejjas et al. -0.010 0.219 0.648 -0.115 0.254 0.652 -0.104 0.266 0.696
McQuillin et al. 0.228 0.113 0.043 0.224 0.129 0.081 0.159 0.132 0.229
Grigoroiu-Serbanescu 
et al.: German sample
0.012 0.097 0.906 0.040 0.110 0.714 0.070 0.113 0.538
Grigoroiu-Serbanescu 
et al.: Polish sample
0.193 0.126 0.126 0.222 0.146 0.130 0.196 0.150 0.193
Grigoroiu-Serbanescu 
et al.: Romanian sample
-0.321 0.191 0.093 -0.420 0.223 0.060 -0.431 0.231 0.062
Grigoroiu-Serbanescu 
et al.: Russian sample
0.057 0.168 0.736 0.164 0.195 0.400 0.267 0.201 0.184
Lavebratt et al. 0.092 0.100 0.354 0.128 0.113 0.260 0.143 0.116 0.216
Soronen et al. 0.253 0.106 0.017 0.240 0.121 0.048 0.164 0.126 0.192
Vikii et al. -0.276 0.174 0.112 -0.298 0.195 0.125 -0.263 0.201 0.189
Halmai et al. -0.156 0.141 0.267 -0.149 0.164 0.364 -0.092 0.170 0.589
Backlund et al. -0.182 0.106 0.087 -0.169 0.126 0.164 -0.106 0.121 0.381
MARS study 0.228 0.106 0.032 0.200 0.121 0.097 0.109 0.124 0.380
Meta-analysis 0.056 0.044 0.011 0.074 0.049 0.008 0.082 0.048 0.009
Beta is given as log(odds ratio) with the respective se (standard error) of the log(odds ratio) 
p-values < 0.05 are depicted in italic
p-values < 0.017, hence surviving multiple-testing over all models, are depicted in bold.
